Halozyme Therapeutics (HALO)

Halozyme Therapeutics

CEO: Helen Torley, M.B. Ch. B., M.R.C.P.

Headquarters: San Diego, California

URL: www.halozyme.com

Investment Date: January 2004

Initial Funding: $8.1 Million

Trading Venue: NASDAQ GS

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies.

In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego, CA.

Halozyme Therapeutics

DISCLAIMER

This website and the information herein is proprietary and confidential and is being presented by Montrose Capital Partners and its affiliates and subsidiaries (“Montrose”) to provide an overview of the Montrose business operations, capabilities and related products/services. You agree to treat this information, including information about possible future transactions, transaction structures and their terms, in strict confidence, not to disclose such information to any other party and not to use such information for any purpose other than in evaluating an interest, if any, in the proposed transactions.

This website was prepared by Montrose for illustration and informational purposes only, and should not be construed as a solicitation to effect, attempt to effect, either transactions in securities or the rendering of personalized investment advice. This website is not to be construed as a recommendation or an offer to sell or a solicitation of an offer to buy securities. Any opinions or comments expressed herein are not necessarily representative of the opinions and views of Montrose or its management, employees, agents or other representatives. Any views, opinions and advice provided in this website has been prepared without taking into account the investment objectives, financial objectives, situation or specific needs of any individual person. Certain information in this website has been derived from publicly available sources that we believe to be accurate; however, we have not verified such information and no rewebsite or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information or opinions and conclusions, if any, in this website. No rewebsite is being made that any investment undertaken, will or is likely to achieve profits or avoid substantial losses. There is a risk of substantial loss in all transactions. To the maximum extent permitted by law, neither Montrose or its management, employees, agents or any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this website.

Any dissemination, distribution or reproduction of this website is strictly prohibited without the consent of Montrose. No part of this website may be reproduced, stored, or transmitted by any means without the express written consent of Montrose. All brands, company names, and product names are trademarks or registered trademarks of their respective holder.

© 2017 Montrose Partners. All rights reserved.

Agree